These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

563 related items for PubMed ID: 10395845

  • 1. Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia.
    Zaunders JJ, Cunningham PH, Kelleher AD, Kaufmann GR, Jaramillo AB, Wright R, Smith D, Grey P, Vizzard J, Carr A, Cooper DA.
    J Infect Dis; 1999 Aug; 180(2):320-9. PubMed ID: 10395845
    [Abstract] [Full Text] [Related]

  • 2. Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.
    Plana M, Ferrer E, Martínez C, Podzamczer D, García F, Maleno MJ, Barceló JJ, García A, Barberá MJ, Lacarcel M, Miró JM, Gallart T, Gatell JM.
    Antivir Ther; 2004 Apr; 9(2):197-204. PubMed ID: 15134181
    [Abstract] [Full Text] [Related]

  • 3. Alterations in T cell phenotype and human immunodeficiency virus type 1-specific cytotoxicity after potent antiretroviral therapy.
    Seth A, Markee J, Hoering A, Sevin A, Sabath DE, Schmitz JE, Kuroda MJ, Lifton MA, Hirsch MS, Collier AC, Letvin NL, McElrath MJ.
    J Infect Dis; 2001 Mar 01; 183(5):722-9. PubMed ID: 11181148
    [Abstract] [Full Text] [Related]

  • 4. Residual viraemia in HIV-1-infected patients with plasma viral load <or=20 copies/ml is associated with increased blood levels of soluble immune activation markers.
    Ostrowski SR, Katzenstein TL, Pedersen BK, Gerstoft J, Ullum H.
    Scand J Immunol; 2008 Dec 01; 68(6):652-60. PubMed ID: 19055701
    [Abstract] [Full Text] [Related]

  • 5. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
    Gray CM, Schapiro JM, Winters MA, Merigan TC.
    AIDS Res Hum Retroviruses; 1998 May 01; 14(7):561-9. PubMed ID: 9591710
    [Abstract] [Full Text] [Related]

  • 6. HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation.
    Steel A, Cox AE, Shamji MH, John L, Nelson M, Henderson DC, Gotch FM, Gazzard BG, Kelleher P.
    Antivir Ther; 2007 May 01; 12(6):971-5. PubMed ID: 17926652
    [Abstract] [Full Text] [Related]

  • 7. Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine.
    Jankelevich S, Mueller BU, Mackall CL, Smith S, Zwerski S, Wood LV, Zeichner SL, Serchuck L, Steinberg SM, Nelson RP, Sleasman JW, Nguyen BY, Pizzo PA, Yarchoan R.
    J Infect Dis; 2001 Apr 01; 183(7):1116-20. PubMed ID: 11237839
    [Abstract] [Full Text] [Related]

  • 8. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA.
    Goicoechea M, Smith DM, Liu L, May S, Tenorio AR, Ignacio CC, Landay A, Haubrich R.
    J Infect Dis; 2006 Jul 01; 194(1):29-37. PubMed ID: 16741879
    [Abstract] [Full Text] [Related]

  • 9. CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy.
    Deeks SG, Hoh R, Grant RM, Wrin T, Barbour JD, Narvaez A, Cesar D, Abe K, Hanley MB, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK.
    J Infect Dis; 2002 Feb 01; 185(3):315-23. PubMed ID: 11807713
    [Abstract] [Full Text] [Related]

  • 10. Down-regulation of interleukin-7 receptor (CD127) in HIV infection is associated with T cell activation and is a main factor influencing restoration of CD4(+) cells after antiretroviral therapy.
    Benito JM, López M, Lozano S, González-Lahoz J, Soriano V.
    J Infect Dis; 2008 Nov 15; 198(10):1466-73. PubMed ID: 18847371
    [Abstract] [Full Text] [Related]

  • 11. CD4+ T cell recovery beyond the first year of complete suppression of viral replication during highly active antiretroviral therapy is not influenced by CD8+ T cell activation.
    Benito JM, Lopez M, Lozano S, Ballesteros C, Capa L, Martinez P, Gonzalez-Lahoz J, Soriano V.
    J Infect Dis; 2005 Dec 15; 192(12):2142-6. PubMed ID: 16288380
    [Abstract] [Full Text] [Related]

  • 12. CD8+ anti-human immunodeficiency virus suppressor activity (CASA) in response to antiretroviral therapy: loss of CASA is associated with loss of viremia.
    Wilkinson J, Zaunders JJ, Carr A, Cooper DA.
    J Infect Dis; 1999 Jul 15; 180(1):68-75. PubMed ID: 10353863
    [Abstract] [Full Text] [Related]

  • 13. RANTES production by T cells and CD8-mediated inhibition of human immunodeficiency virus gene expression before initiation of potent antiretroviral therapy predict sustained suppression of viral replication.
    Fransen S, Copeland KF, Smieja M, Smaill F, Rosenthal KL.
    J Infect Dis; 2000 Feb 15; 181(2):505-12. PubMed ID: 10669333
    [Abstract] [Full Text] [Related]

  • 14. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens.
    Rinaldo CR, Liebmann JM, Huang XL, Fan Z, Al-Shboul Q, McMahon DK, Day RD, Riddler SA, Mellors JW.
    J Infect Dis; 1999 Feb 15; 179(2):329-36. PubMed ID: 9878015
    [Abstract] [Full Text] [Related]

  • 15. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy.
    Günthard HF, Wong JK, Spina CA, Ignacio C, Kwok S, Christopherson C, Hwang J, Haubrich R, Havlir D, Richman DD.
    J Infect Dis; 2000 Feb 15; 181(2):522-31. PubMed ID: 10669335
    [Abstract] [Full Text] [Related]

  • 16. In vitro induction of HIV-1 replication in resting CD4(+) T cells derived from individuals with undetectable plasma viremia upon stimulation with human T-cell leukemia virus type I.
    Moriuchi H, Moriuchi M.
    Virology; 2000 Dec 20; 278(2):514-9. PubMed ID: 11118373
    [Abstract] [Full Text] [Related]

  • 17. Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults.
    Notermans DW, Pakker NG, Hamann D, Foudraine NA, Kauffmann RH, Meenhorst PL, Goudsmit J, Roos MT, Schellekens PT, Miedema F, Danner SA.
    J Infect Dis; 1999 Oct 20; 180(4):1050-6. PubMed ID: 10479130
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P, Chetchotisakd P, Anunnatsiri S, Boonyaprawit P.
    Antivir Ther; 2005 Oct 20; 10(8):911-6. PubMed ID: 16430196
    [Abstract] [Full Text] [Related]

  • 19. Limited long-term naive CD4+ T cell reconstitution in patients experiencing viral load rebounds during HAART.
    Choremi-Papadopoulou H, Tsalimalma K, Dafni U, Dimitracopoulou A, Kordossis T.
    J Med Virol; 2004 Jun 20; 73(2):235-43. PubMed ID: 15122798
    [Abstract] [Full Text] [Related]

  • 20. Antiretroviral therapy initiation during primary HIV infection enhances both CD127 expression and the proliferative capacity of HIV-specific CD8+ T cells.
    Lécuroux C, Girault I, Boutboul F, Urrutia A, Goujard C, Meyer L, Lambotte O, Chaix ML, Martinez V, Autran B, Sinet M, Venet A, ANRS PRIMO Cohort, ANRS HIC Study Group, ANRS ALT Cohort, ANRS HIC Study Group.
    AIDS; 2009 Aug 24; 23(13):1649-58. PubMed ID: 19617814
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.